[Consensus on diagnosis and treatment of sudden hearing loss. Asociación Madrileña de ORL].
Idiopathic sudden sensorineural hearing loss is an unexplained unilateral hearing loss with onset over a period of less than 72 hours, without other known otological diseases. We present a consensus on the diagnosis, treatment and follow-up of this disease, designed by AMORL, after a systematic review of the literature from 1966 to June 2010. Diagnosis of sudden sensorineural hearing loss is based on mandatory otoscopy, acoumetry, tonal audiometry, speech audiometry, and tympanometry. After clinical diagnosis is settled, and before treatment is started, a full analysis should be done and an MRI should be requested later. Treatment is based on systemic corticosteroids (orally in most cases), helped by intratympanic doses as rescue after treatment failures. Follow-up should be done at day 7, with tonal and speech audiometries, and regularly at 15, 30, and 90 days after start of therapy, and after 12 months. By consensus, results after treatment should be reported as absolute dBs recovered in pure tonal audiometry, as improvement in the recovery rate in unilateral cases, and as improvement in speech audiometry.
Servicio de Otorrinolaringología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain. gplaza.hflr@salud.madrid.org
Guillermo
G
Plaza
Enrique
E
Durio
Carlos
C
Herráiz
Teresa
T
Rivera
José Ramón
JR
García-Berrocal
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D020274:Autoimmune Diseases of the Nervous System / Q000175:diagnosis / Q000188:drug therapy; D002648:Child; D003952:Diagnostic Imaging; D003939:Diagnostic Techniques, Otological; D007758:Ear, Inner / Q000098:blood supply; D005500:Follow-Up Studies; D006312:Hearing Loss, Bilateral / Q000175:diagnosis / Q000209:etiology; D003639:Hearing Loss, Sudden / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D015201:Meta-Analysis as Topic; D008833:Microcirculation; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D014665:Vasodilator Agents / Q000627:therapeutic use; D014777:Virus Diseases / Q000150:complications / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D014665:Vasodilator Agents